Back to News
Market Impact: 0.6

Citi reiterates Buy rating on Lumen stock, sees upside from divestiture

CLUMNTBNPQY
M&A & RestructuringCompany FundamentalsCredit & Bond MarketsAnalyst InsightsAnalyst EstimatesCorporate Guidance & OutlookCorporate EarningsArtificial Intelligence
Citi reiterates Buy rating on Lumen stock, sees upside from divestiture

Citi has reiterated a Buy rating and $6.00 price target for Lumen (LUMN), projecting significant upside to fiscal year 2026 free cash flow (FCF) and accelerated net debt deleveraging. The firm's above-consensus FY26 FCF forecast of $1.3 billion, coupled with strategic divestitures like the $5.75 billion Mass Markets fiber sale to AT&T and financial restructuring, is expected to reduce net debt leverage from 4.4x to 3.3x EBITDA by 2026. Citi believes the market undervalues Lumen's ongoing efforts to strengthen its balance sheet and enhance equity value, despite a 'Fair' overall financial health score and a more cautious Neutral rating from BNP Paribas Exane.

Analysis

Citigroup's reiteration of a Buy rating and a $6.00 price target for Lumen Technologies (LUMN) underscores a strong conviction in the company's ongoing balance sheet transformation, a view that starkly contrasts with the stock's current $4.36 price. The core of this bullish thesis rests on an above-consensus fiscal year 2026 free cash flow (FCF) forecast of $1.3 billion, or approximately $1 per share, which dwarfs the consensus estimate of just $0.2 billion. Citi projects this superior cash generation, driven by strategic divestitures and cost efficiencies, will accelerate deleveraging, reducing net debt from 4.4x EBITDA in Q1 2025 to a proforma 3.3x by 2026. This outlook is supported by concrete strategic actions, chiefly the pending $5.75 billion cash sale of its Mass Markets fiber business to AT&T and a debt refinancing expected to cut annual interest expenses by about $100 million. However, this optimism is not universal. BNP Paribas holds a more cautious Neutral rating, albeit with a recently raised $4.00 price target, and InvestingPro data flags a middling "Fair" Financial Health Score of 2.13 out of 5. These counterpoints suggest potential execution risks in the extensive restructuring, creating a clear debate between Citi's aggressive deleveraging scenario and a more subdued market sentiment.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.